Underdog Launches With $4M to Target “Toxic” Form of Cholesterol
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in
Tag: Cholesterol
Lactosyl-β-cyclodextrin against Hepatomegaly in Niemann-Pick Type C Disease
The first paper in the special issue of Nanomaterials “Nanoconstructs Based on Cyclodextrins” has been published. Mono-lactosyl β-CD (mono-Lac-β-CD) diminished
Effect of CD on the antiaging drug: rapamycin
Rapamycin (also known as sirolimus) is a macrolide compound produced by the bacterium Streptomyces hygroscopicus. It is immunosuppressant used to
Novel polyrotaxane for Niemann Pick disease type C treatment
The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
Cyclodextrins in veterinary medicine (Part 2)
In our previous post we talked about the “classical” usage of cyclodextrins in veterinary medicine. Now let’s see some non-usual
DIMEB in biotechnology
Heptakis(2,6-di-O-methyl) beta-cyclodextrin is a single isomer with high solubility in cold water, but it crystallizes from water at increased temperatures.
FDA Approved Development of VAR 200 for Treatment of FSGS
Variant Pharmaceuticals, Inc received US Food and Drug Administration (FDA) has approval for the development of VAR 200 (2-hydroxypropyl-β-cyclodextrin, or
Different cyclodextrins to treat NPC
If you are following advances in the re-discovery of cyclodextrins as APIs, there is quite a race among the candidates
Cyclodextrins as theranostics
The application of cyclodextrins as excipients is wellspread, common knowledge worldwide. Their application as APIs is getting huge publicity, developments